H-TYR-D-ALA-GLY-PHE-MET-NH2 manufacturers
|
| | H-TYR-D-ALA-GLY-PHE-MET-NH2 Basic information |
| Product Name: | H-TYR-D-ALA-GLY-PHE-MET-NH2 | | Synonyms: | TYR-D-ALA-GLY-PHE-MET-NH2;TYR-D-ALA-GLY-PHE-MET-NH2 ACOH H2O;ala(2)-enkephalinamide-me;ENKEPHALINAMIDE, [D-ALA2, MET5];ENKEPHALIN, MET- (D-ALA2; AMIDE);[D-ALA2,MET5]-ENKEPHALINAMIDE;[D-ALA2,MET5]-ENKEPHALINAMIDE ACOH H2O;D-ALA2-MET-ENKEPHALINAMIDE | | CAS: | 61090-95-7 | | MF: | C28H38N6O6S | | MW: | 586.71 | | EINECS: | | | Product Categories: | | | Mol File: | 61090-95-7.mol |  |
| | H-TYR-D-ALA-GLY-PHE-MET-NH2 Chemical Properties |
| Boiling point | 1057.351±65.00 °C(Press: 760.00 Torr)(predicted) | | density | 1.286±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | storage temp. | -15°C | | pka | 9.969±0.15(predicted) |
| | H-TYR-D-ALA-GLY-PHE-MET-NH2 Usage And Synthesis |
| Uses | [D-Ala2]-Met-Enkephalinamide, an opioid peptide, is a potent opioid agonist. [D-Ala2]-Met-Enkephalinamide decreases bile flow by a central mechanism. [D-Ala2]-Met-Enkephalinamide has analgesic properties[1][2]. | | in vivo | [D-Ala2]-Met-Enkephalinamide decreases bile flow by a central mechanism in Sprague-Dawley rats[1]. | Animal Model: | Male Sprague-Dawley rats (250-320 g)[1] | | Dosage: | 10, 50, 100, 150, and 200 mg/kg | | Administration: | Intracerebroventrical injection | | Result: | Decreased in bile flow that ranged from 12% to 41%.
Decreased bicarbonate secretion into bile.
|
| | References | [1] Bergasa NV, et, al. The opioid peptide analog D-Ala2-Met-enkephalinamide decreases bile flow by a central mechanism. Peptides. 1999;20(8):979-86. DOI:10.1016/s0196-9781(99)00091-1
[2] PERT CB, et, al. [D-Ala2]-Met-Enkephalinamide: A Potent, Long-Lasting Synthetic Pentapeptide Analgesic. 1976 Oct 15;194(4262):330-2. |
| | H-TYR-D-ALA-GLY-PHE-MET-NH2 Preparation Products And Raw materials |
|